Journal of Neurology

, Volume 257, Issue 9, pp 1421–1431

Neurological adverse events associated with anti-tumor necrosis factor alpha treatment


DOI: 10.1007/s00415-010-5591-7

Cite this article as:
Tristano, A.G. J Neurol (2010) 257: 1421. doi:10.1007/s00415-010-5591-7


Anti-tumor necrosis factor alpha (TNF-α) drugs have been successfully used for the treatment of rheumatic autoimmune diseases including rheumatoid arthritis (RA), psoriatic arthritis, psoriasis, ankylosing spondylitis (AS), juvenile chronic arthritis, and Crohn’s disease. However, they have been associated with different neurological disorders, including alterations of peripheral nerves, multiple sclerosis (MS), optic neuritis (ON) and acute transverse myelitis (ATM). This article reviews the most current aspect regarding neurological adverse events associated with anti-TNF-α drugs with emphasis on the possible explanations for this relation and the pathogenic mechanism of TNF-α in neurological disorders.


Tumor necrosis factor alpha (TNF-α) Anti-TNF-α Neurological adverse events Demyelinating disease Infliximab Etanercept Adalimumab 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Centro Médico Docente La TrinidadCaracasVenezuela
  2. 2.Centro Médico CarpetanaMadridSpain

Personalised recommendations